Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: “This is the first time an effort has been made, on this scale, to provide Indian physicians with a sensitive, objective

Cambridge Cognition Holdings plc (LON: COG), which develops and markets neuroscience technology to assess brain health, announces a trading update for the year ending 31 December 2018. For FY2018, the

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: “We are pleased to welcome another pharmaceutical partner to the growing number who trust our neuroscience technologies with the collection and

Commenting on the results Steven Powell, Chief Executive Officer of Cambridge Cognition, said: “The first half has been characterised by the Company delivering against its promised strategy as evidenced by

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: “We are pleased to confirm this first contract for use of the novel voice platform in an industry sponsored clinical trial

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: “This new platform is a key step in the Company’s strategy for growth; developing innovative near-patient digital technologies to optimise drug

Dr Steven Powell, CEO, Cambridge Cognition, said: “Through this collaboration we hope to widen the distribution channels of our medical software products to an established customer base in the US

Cambridge Cognition Holdings plc (LON: COG), which develops and markets digital solutions to assess brain health, has today announced a brand new software product to assess mental health and wellbeing